Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01494012 · ClinicalTrials.gov registry record · Phase 1
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
A Phase 1 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01494012: Clinical Trial Phase 1 study, sponsored by Stanford University.
NCT01494012 is a Phase 1 study that was terminated before completion, run by Stanford University. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01494012, a Phase 1 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy (SBRT) in treating patients with metastatic or recurrent ovarian cancer or primary peritoneal cancer. SBRT may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
Interventions
- OTHER questionnaire administration
- RADIATION stereotactic body radiation therapy
- PROCEDURE positron emission tomography
- PROCEDURE computed tomography
- DRUG fludeoxyglucose F 18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-04 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01494012
The ClinicalTrials.gov registry entry for NCT01494012 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which questionnaire administration is the first listed.
NCT01494012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01494012 about?
NCT01494012 is a clinical study titled "Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer". This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy (SBRT) in treating patients with metastatic or recurrent ovarian cancer or primary peritoneal cancer. SBRT may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
What is the current status of trial NCT01494012?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2012-04. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01494012?
The interventions under investigation include: questionnaire administration (OTHER), stereotactic body radiation therapy (RADIATION), positron emission tomography (PROCEDURE), computed tomography (PROCEDURE), fludeoxyglucose F 18 (DRUG).
Who is sponsoring clinical trial NCT01494012?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.